Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
-
Authors
-
-
Fazio, Nicola1
-
Granberg, Dan2
-
Grossman, Ashley3
-
Saletan, Stephen4
-
Klimovsky, Judith4
-
Panneerselvam, Ashok4
-
Wolin, Edward M5
-
1
European Institute of Oncology, Milan, Italy. Electronic address: [email protected]
,
(Italy)
-
2
Departments of Medical Sciences and Endocrine Oncology, Uppsala University, Uppsala, Sweden.
,
(Sweden)
-
3
Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital University of Oxford, Oxford, England.
-
4
Novartis Pharmaceuticals Corp, Florham Park, NJ.
-
5
Cedars-Sinai Medical Center, Los Angeles, CA.
- Type
- Published Article
- Journal
-
CHEST Journal
- Publisher
-
Elsevier
- Publication Date
-
April 2013
- Volume
-
143
- Issue
-
4
- Pages
-
955–962
- Identifiers
-
DOI: 10.1378/chest.12-1108
-
PMID: 23187897
- Source
-
Medline
- License
-
Unknown
Abstract
ClinicalTrials.gov; No.: NCT00412061
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/07/2017 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at
https://www.ncbi.nlm.nih.gov/pubmed/23187897
Report this publication